These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10608980)

  • 1. [Selective estrogen receptor modulators (SERM's) in postmenopausal women].
    Kleiverda G
    Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2446-7. PubMed ID: 10608980
    [No Abstract]   [Full Text] [Related]  

  • 2. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women.
    Bjarnason NH
    Dan Med Bull; 2005 May; 52(2):64-81. PubMed ID: 16009050
    [No Abstract]   [Full Text] [Related]  

  • 4. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
    Hart W; Netelenbos JC
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1771-6. PubMed ID: 10494328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis guidelines.
    Yendt ER
    CMAJ; 2003 Jun; 168(13):1644; author reply 1645-6. PubMed ID: 12821611
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T; Mizunuma H
    Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
    Urano T
    Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Not all SERMs are created equal.
    Goldstein SR
    Menopause; 2006; 13(3):325-7. PubMed ID: 16735926
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effects of raloxifene on bone loss and fracture risk in the menopausal woman].
    Vignot E; Meunier PJ
    Contracept Fertil Sex; 1999 Dec; 27(12):858-60. PubMed ID: 10676043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does raloxifene reduce risk of vertebral fractures? Is this another, brighter way to treat osteoporosis?
    Hathirat S; Evans MF
    Can Fam Physician; 2001 Oct; 47():1982-4. PubMed ID: 11723592
    [No Abstract]   [Full Text] [Related]  

  • 11. Raloxifene.
    Gass ML
    South Med J; 1999 Nov; 92(11):1120-3. PubMed ID: 10586846
    [No Abstract]   [Full Text] [Related]  

  • 12. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Raloxifene in postmenopausal women].
    Trémollières F; Ribot C
    Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [MORE study(raloxifene)].
    Itabashi A
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():442-9. PubMed ID: 15035168
    [No Abstract]   [Full Text] [Related]  

  • 16. Drugs for prevention and treatment of postmenopausal osteoporosis.
    Treat Guidel Med Lett; 2002 Nov; 1(3):13-8. PubMed ID: 15529101
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.
    Adomaityte J; Farooq M; Qayyum R
    Thromb Haemost; 2008 Feb; 99(2):338-42. PubMed ID: 18278183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments in osteoporosis treatments.
    Miller CA
    Geriatr Nurs; 2000; 21(4):219, 223. PubMed ID: 10945890
    [No Abstract]   [Full Text] [Related]  

  • 19. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
    Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies.
    Meadows ES; Stock J; Johnston JA
    Med Decis Making; 2006; 26(6):633-5; author reply 636-7. PubMed ID: 17099202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.